Which regimens does NCCN consider useful in select circumstances of multiple myeloma (MM)?

Updated: Sep 30, 2019
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

The NCCN considers the following regimens useful in certain circumstances (eg, two-drug regimens may be appropriate for elderly or frail patients):

  • Bortezomib/dexamethasone (category 1)
  • Bortezomib/thalidomide/dexamethasone (category 1)
  • Lenalidomide/dexamethasone (category 1)
  • Dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide/bortezomib (VTD-PACE)

Patients should be assessed for response after two cycles of one of the above regimens.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!